“I’m incredibly proud of all the patients who participated in the trial; their contribution has allowed us to gather the evidence needed to improve treatment of cervical cancer patients everywhere.”The new treatment approach also cuts the risk of cervical cancer returning or relapsing by 35%, the researchers added. All had locally advanced cervical cancer, though none had tumors that had spread to other organs. “Timing is everything when you’re treating cancer,” Dr. Iain Foulkes, executive director of research and innovation at Cancer Research UK, said in the group's news release. Cisplatin-based chemotherapy is currently the most commonly used method of treating cervical cancer, improving survival rates by 30% to 50%. “Of the 4,400 deaths from cervical cancer, none of them get screened every year.”More informationThe National Cancer Institute has more on cervical cancer.

Source: Daily Sun October 17, 2024 18:13 UTC